Canada Med Stop – FDA Warning Letter, Aug 31, 2025

The FDA issued a warning letter to Canada Med Stop on September 9, 2025, following a review of their website in August 2025. The inspection revealed that the company offers compounded semaglutide drug products with misleading claims, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA). These claims falsely suggest that the compounded products are equivalent to FDA-approved medications, which they are not, thereby misbranding the products.

The regulatory framework under the FDCA prohibits the introduction of misbranded drugs into interstate commerce, as outlined in section 301(a). The FDA highlighted specific misleading claims on the company"s website, such as labeling the products as "FDA-Approved Medication" and implying they contain "The same active ingredient in branded weight loss medications."

The FDA requires Canada Med Stop to take immediate corrective actions, including ceasing the use of misleading language. The company must respond within 15 working days, detailing the steps taken to rectify the violations and prevent recurrence. Failure to comply may result in legal actions, including product seizure and injunctions. The FDA also warned that misbranded products could be detained or refused entry into the U.S., and foreign regulatory bodies may be informed of these violations. The company is urged to ensure full compliance with federal laws and FDA regulations.